Receptor mapping using methoxy phenyl piperazine derivative: Preclinical PET imaging

Area of Science:

• Neuroscience
• Radiochemistry
• Pharmacology

Background:

• Metabotropic glutamate receptor subtype 1 (mGluR1) is implicated in neuropsychiatric disorders.
• Developing specific PET radioligands is crucial for in vivo imaging of mGluR1.

Purpose of the Study:

• To synthesize and evaluate a novel 2-methoxyphenyl piperazine derivative for its binding specificity and suitability in mapping mGluR1.
• To assess the potential of this compound as a PET radioligand for brain imaging.

Main Methods:

• Synthesis of N-(2-(4-(2-Methoxyphenyl)piperazin-1-yl)ethyl)-N-methylpyridin-2-amine.
• Radiolabelling with Carbon-11 ([¹¹C]) via methylation.
• In vitro autoradiography and in vivo PET imaging and biodistribution studies in animal models.
• Assessment of haemolysis to determine low toxicity.

Main Results:

• The PET radioligand was synthesized with high purity (98.9%) and yield (52 ± 6%).
• Specific activity ranged from 72-93 GBq/µmol.
• Low toxicity was indicated by <10% haemolysis after 24h incubation.
• In vitro and in vivo studies confirmed high uptake in mGluR1-rich brain regions (cerebellum, thalamus, striatum) and a direct correlation with receptor distribution.
• High initial brain uptake (4.18 ± 0.48) and negligible uptake in pons were observed.

Conclusions:

• The novel radioligand demonstrates high binding specificity and uptake in mGluR1-rich brain regions.
• The compound is suitable for PET imaging of mGluR1, offering potential for studying neuropsychiatric disorders.